Table 2.
Types of prognostic gene expression-based assays
| Platform | Description | Validated | Site | Technology | Risk classification | Prospective randomized study | Evidence |
|---|---|---|---|---|---|---|---|
| Oncotype | 21-gene signature | N0 (pre and postmenopausal) N1(postm) | Central | Microarray | Recurrence Score (RS) Low, Intermediate, High |
TAILORx [46] RxPONDER [50] |
IA |
| Mammaprint |
70-gene signature Tumoral subtype Blue Print (Luminal, Basal, ERBB2) |
N0 N1 (postm) | Central | RT-qPCR | Ultralow, Low, High | MINDACT [45] | IA |
| Endopredict | 11-gene signature | N0 N1 (postm) | Local labs | RT-qPCR | Low, High EPclin | No | IB |
| Prosigna | 50-gene signature tumoral subtype (Luminal A, B, HER2-enriched, Basal-like) | N0 (postm) | Local labs | nCounter (Direct mRNA counting) | Low, intermediate, high (ROR) Intrinsic subtypes (15–19) | OPTIMA (in process) | IB |